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Abstract
A Hepatocellular (HCC) Aggressiveness Index was recently constructed, consisting of the sum of the scores for
the 4 clinical parameters of maximum tumor size, multifocality, presence of portal vein thrombus and blood alpha-
fetoprotein levels. It was observed that there was an association with several liver function tests. We have now
formed a Liver Index from the 4 liver parameters with the highest hazard ratios with respect to HCC aggressiveness,
namely: blood total bilirubin, gamma glutamyl transpeptidase (GGTP), albumin and platelet levels (cirrhosis
surrogate). We found that the scores for the Liver Index related significantly to survival, but also to the
Aggressiveness Index and to its individual HCC components as well as showing significant trends with the
components. These results support the hypothesis that liver function is not only an important prognostic factor in
HCC patients, but may also be involved in HCC biology and aggressiveness. Blood albumin, GGTP, albumin and
platelet levels were used to create a Liver Index that related significantly to parameters of HCC aggressiveness.
Keywords: HCC; Aggressiveness index; Survival; Liver function
Abbreviations HCC: Hepatocellular Carcinoma; AFP: Alpha-
Fetoprotein; GGTP: Gamma Glutamyl Transpeptidase; PVT: Portal
Vein Thrombosis; MTD: Maximum Tumor Diameter; CT:
Computerized Axial Tomography Scan; Alb: Albumin; Plts: Platelets;
Bil: Bilirubin
Introduction
Human hepatocellular carcinoma (HCC) has 4 clinical
characteristics that are used to evaluate treatment options and
prognosis (in addition to metastasis). They are: maximum tumor
diameter (MTD), presence or absence of of tumor multifocality,
presence or absence of portal vein thrombus (PVT) and blood alpha-
fetoprotein (AFP) level. These 4 parameters were recently integrated
into an Aggressiveness Index, with points allotted to the level of each
separate parameter and the total were then summed [1]. This approach
was then validated in another, much larger dataset [2]. It was also
observed that with each score level in the Aggressiveness Index, there
was a significant difference in patient survival. Furthermore, there
were increased mean values for several common liver function
parameters, with increase in the Aggressiveness Index score.
The analysis of a possible relationship between indices of HCC
aggressiveness and liver function parameters, has been extended in the
current work, by examining whether liver function parameter values in
patients with HCC might be useful in predicting HCC aggressiveness.
We found that a composite Liver Score, comprising blood total
bilirubin, GGTP, albumin and blood platelet levels (surrogate for
cirrhosis) relate to both trends in the individual HCC aggressiveness
components, and also to the Aggressiveness Index.
Methods
Construction of the liver index
The Liver Index is the sum of the scores for blood GGTP+total
bilirubin+albumin+platelet levels. The scores were assigned as follows:
GGTP IU/ml (cut-off): GGTP<100; 100 ≤ GGTP ≤ 200; GGTP>200
levels, were assigned a score of 1, 2, 3 respectively.
Carr et al., J Integr Oncol 2016, 5:3 
DOI: 10.4172/2329-6771.1000178
Research Article OMICS International
J Integr Oncol, an open access journal
ISSN:2329-6771
Volume 5 • Issue 3 • 1000178
Jo
ur
na
l o
f In
tegrative Oncology
ISSN: 2329-6771
Journal of Integrative Oncology
Bilirubin mg/dl (cut-off): Bilirubin<1.5; 1.5 ≤ Bilirubin ≤ 2.5;
Bilirubin>2.5 levels, were assigned a score of 1, 2, 3 respectively.
Albumin g/dl (cut-off): Albumin>3.5; 2.5 ≤ Albumin ≤ 3.5;
Albumin<2.5 levels, were assigned a score of 1, 2, 3 respectively.
Platelets×109/l (cut-off): Platelets<100; 100 ≤ Platelets ≤ 150;
Platelets>150 levels, were assigned a score of 1, 2, 3 respectively.
The point scores were derived from dividing the full range of each
parameter into terciles, each increasing tercile then being given an
increased point of 1, 2 or 3.
The Liver Index score was divided into three groups for Kaplan-
Meier Survival and Cox analysis: a, score=4; b, 4<score ≤ 8; and c,
score>8.
Patients and Data Collection
Data collection
We retrospectively analyzed prospectively-collected data in the
Italian Liver Cancer (ITA.LI.CA) study group database of 2706 HCC
patients accrued till 2008 at 11 centers [1,2] who had full baseline
tumor parameter data, including CT scan information on maximum
tumor diameter (MTD), number of tumor nodules and presence of
PVT and plasma AFP levels; blood counts; routine blood liver function
tests, (total bilirubin, GGTP, albumin); demographics and survival
information. ITA.LI.CA database management conforms to Italian
legislation on privacy and this study conforms to the ethical guidelines
of the Declaration of Helsinki. Approval for this retrospective study on
de-identified HCC patients was obtained by the Institutional Review
Board of participating centers.
Aggressiveness Index was calculated as the sum of scores:
MTD (cm, in tertiles): MTD<4.5; 4.5 ≤ MTD ≤ 9.6; MTD>9.6;
scores 1, 2, 3 respectively;
AFP ng/ml (cut-off): AFP<100; 100 ≤ AFP ≤ 1000; AFP>1000;
scores 1, 2, 3 respectively;
PVT (No/Yes): PVT(No); PVT(Yes); scores 1, 3 respectively;
Number of Tumor Nodules: Nodules ≤ 3; Nodules>3; scores 1, 3
respectively.
Statistical analysis
Mean and SD for continuous variables were used as indices of
centrality and dispersion of the distribution.
It was necessary, for non-normally distributed values, for the
continuous variables, to use non-parametric methods. We used the
Kruskal-Wallis rank test for differences of the parameters among the
three categories of the Liver Index, and the Wilcoxon rank-sum
(Mann-Whitney) test for the comparisons of the Aggressiveness Index
between two categories at a time of the Liver Index score.
The test for trend was used to evaluate the trend of the
Aggressiveness Index means among Liver index score categories.
Linear regression and multiple linear regression models were used
for the association of the Aggressiveness Index score on the Liver
Index score (A), and on each serum variable, Gamma Glutamyl
Transpeptidase (GGTP), Total Bilirubin (Bilirubin), Albumin (Alb),
and Platelets (Plt), included together in the model (B). The results were
presented as coefficients (β) with 95% C.I.
Patient survival between the three categories of the Liver Index
score was estimated with the Kaplan-Meier method and comparison of
survival was made with the Breslow (generalized Wilcoxon) test. The
Breslow test was used, as opposed to the log rank test, due to the large
proportion of patients who died early.
The Cox proportional hazards model was applied to evaluate the
predictive factors as categories of Liver Index score associated with
overall survival. The results were presented as Hazard Ratio (HR) with
95% C.I.
In all models, for Cox regression model, the HR, and for the Linear
regression and Logistic regression, the β, represent the variation of the
dependent variable, for one-unit variation of the predictor variable
considered both as dummy or as continuous variable.
When testing the hypothesis of significant association, p-value was
<0.05, two tailed for all analyses. Statistical analysis was performed
with StataCorp. 2007. Stata Statistical Software: release 10. College
Station, TX: StataCorp LP.
Results
Liver index and its relationship to patient survival
The construction of the Liver Index is shown in Table 1, and
comprises scores of 1, 2 or 3 which are assigned to the values in an
HCC patient for blood levels of GGTP, total bilirubin, albumin and
platelet levels.
Score
1 2 3
GGTP (IU/ml) <100 100 - 200 >200
Total Bilirubin (mg/dl) <1.5 1.5 - 2.5 >2.5
Albumin (g/dl) >3.5 2.5 - 3.5 <2.5
Platelets (x109/l) <100 100 - 150 >150
The Liver Index is the sum of the scores for GGTP+Bil+Alb+Platelets:
GGTP (cut-off): GGTP<100; 100 ≤ GGTP ≤ 200; GGTP>200; scores 1, 2, 3
respectively.
Bil (cut-off): Bil<1.5; 1.5 ≤ Bil ≤ 2.5; Bil>2.5; scores 1, 2, 3 respectively.
Alb (cut-off): Alb>3.5; 2.5 ≤ Alb ≤ 3.5; Alb<2.5; scores 1, 2, 3 respectively.
Platelets (cut-off): Plt<100; 100 ≤ Plt ≤ 150; Plt>150; scores 1, 2, 3 respectively
The Liver Index score was divided into three groups for Kaplan-Meier Survival
plots and Cox analysis: a, score=4; b, 4<score ≤ 8; and c, score>8.
GGTP- Gamma glutamyl transpeptidae; Bil- total bilirubin; Alb- Albumin; Plt-
Platelets.
Table 1: Liver Index as sum of the respective scores.
These 4 parameters were chosen since they had the highest Odds
Ratios (OR) in a multiple regression analysis for the HCC
aggressiveness Index [2], and they were divided into three categories,
each category being given a point score of 1, 2 or 3, respectively. The
total Liver Index scores were then divided into 3 groups for the
purposes of further analysis. A score of 4 was represented as group ‘a’.
A score of 4<score ≤ 8 was represented as group ‘b’. A score of >8 was
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represented as group ‘c’. To examine the relationship of the 3 groups to
survival, a Kaplan-Meier analysis was calculated and shown in Figure
1.
Figure 1: Kaplan-Meier Survival plots between groups of the Liver
Index in total cohort. *Wilcoxon (Breslow) test. The Liver Index is
the sum of the scores for GGTP+Bilirubin+Albumin+Platelets:
GGTP (cut-off): GGTP<100; 100 ≤ GGTP ≤ 200; GGTP>200; for
scores 1, 2, 3 respectively. Bilirubin (cut-off): Bil<1.5; 1.5 ≤ Bil ≤ 2.5;
Bil>2.5; for scores 1, 2, 3 respectively. Albumin (cut-off): Alb>3.5;
2.5 ≤ Alb ≤ 3.5; Alb<2.5; for scores 1, 2, 3 respectively. Platelet (cut-
off): Plt<100; 100 ≤ Plt ≤ 150; Plt>150; for scores 1, 2, 3 respectively.
One-year percent survival probabilities were 90.3%, 75.8% and
38.1% for groups a, b and c, respectively. Three-years percent survival
probabilities were 51.3%, 43.0% and 10.7% for groups a, b and c
respectively. These differences were significant, p<0.0001.
  HR* se(HR) p 95%C.I.
Comparison
s of HRs p
Liver Index        
Score=4
[Ref.
category]
(a) 1 -- -- -- (a) vs (b) <0.001
4<Score ≤
8 (b) 1.41 0.13 <0.001
1.17
to
1.70
(a) vs (c) <0.001
8<Score ≤
12 (c) 4.19 0.54 <0.001
3.26
to
5.40
(b) vs (c) <0.001
*Hazard Ratio;
Liver Index groups: a, score=4; b, 4<score ≤ 8; and c, score>8.
Liver Index is the sum of the scores for GGTP +Bilirubin + Albumin +Platelet
GGTP (cut-off): GGTP<100; 100 ≤ GGTP ≤ 200; GGTP>200; for scores 1, 2, 3
respectively.
Bilirubin (cut-off): Bil<1.5; 1.5 ≤ Bil ≤ 2.5; Bil>2.5; for scores 1, 2, 3 respectively.
Albumin (cut-off): Alb>3.5; 2.5 ≤ Alb ≤ 3.5; Alb<2.5; for scores 1, 2, 3
respectively.
Platelet (cut-off): Plt<100; 100 ≤ Plt ≤ 150; Plt>150; for scores 1, 2, 3
respectively
Table 2: Cox proportional hazard model in HCC patients for death on
Liver Index Score categories in total cohort.
A Cox proportional hazard model for death on the Liver Index
score categories (Table 2), showed significant differences in the Hazard
Ratios (HR), being 1 for group a (arbitrary reference value), 1.4 for
group b (p<0.001) and 4.19 for group c (p<0.001).
Relationship of liver index and its parameters to HCC
aggressiveness
A linear regression model was constructed of the Aggressiveness
Index score on the Liver Index score (Table 3A). We found a positive
association between the Aggressiveness Index and the Liver Index. For
each unit of change in the Liver Index, there was a quarter of a score
increase in the Aggressiveness Index (0, 25). A multiple regression
model was also calculated for all the 4 parameters of the Liver Index
(GGTP, total bilirubin, albumin and platelets) together in the model
(Table 3B). We found that 3 of the individual components used for the
construction of the Liver Index are positively associated with the
Aggressiveness Index. In contrast, however, only the Albumin showed
an inverse association, that is, with an increase in albumin levels, the
Aggressiveness Index decreased. For all of these components there was
a statistically significant association (for all, p<0.001).
β Se(β) p 95% C.I.
(A)
Liver Index score 0.2462 0.0247 <0.001 0.1978 to 0.2945
(B)
GGTP (IU/ml) 0.0013 0.0003 <0.001 0.0007 to 0.0020
Total Bilirubin
(mg/dl)
0.0585 0.0140 <0.001 0.0311 to 0.0859
Albumin (g/dl) -0.3821 0.0554 <0.001 -0.4908 to -0.2733
Platelets (x109/L) 0.0031 0.0005 <0.001 0.0021 to 0.0041
Aggressiveness Index (sum of scores):
MTD (in tertiles): MTD<4.5; 4.5 ≤ MTD ≤ 9.6; MTD>9.6; for scores 1, 2, 3
respectively;
AFP (cut-off): AFP<100; 100 ≤ AFP ≤ 1000; AFP>1000; for scores 1, 2, 3
respectively;
PVT (No/Yes): PVT(No); PVT(Yes); for scores 1, 3 respectively;
Nodules (number): Nodules ≤ 3; Nodules>3; for scores 1, 3 respectively.
Liver Index is the sum of scores:
GGTP (cut-off): GGTP<100; 100 ≤ GGTP ≤ 200; GGTP>200; for scores 1, 2, 3
respectively.
Bilirubin (cut-off): Bil<1.5; 1.5 ≤ Bil ≤ 2.5; Bil>2.5; for scores 1, 2, 3 respectively.
Albumin (cut-off): Alb>3.5; 2.5 ≤ Alb ≤ 3.5; Alb<2.5; for scores 1, 2, 3
respectively.
Platelets (cut-off): Plt<100; 100≤Plt ≤ 150; Plt>150; for scores 1, 2, 3
respectively.
MTD- Maximum Tumor Diameter; AFP- Alpha-fetoprotein; PVT- Portal Vein
Thrombosis; GGTP- Gamma glutamyl transpeptidae; Bil- Total bilirubin; Alb-
Albumin; Plt- Platelets.
Table 3: A) Linear regression model of Aggressiveness Index score on
Liver Index score, B) multiple linear regression model on all
parameters Platelets, GGTP, total Bilirubin and Albumin together in
the model.
We then constructed a table to show the relationship between the
Liver Index groups a, b and c and the Aggressiveness Index scores
(Table 4). Considering the relationship between the two indices,
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Aggressiveness Index and Liver function Index, shown in Table 4, we
found that there was a positive and significant linear trend between
them. The average index values of the Aggressiveness Index increased
with each increase in the Liver index categories and the relative
differences between these average values were all significant (p<0.001,
test for trend), with the exception of the first two categories (‘a’ vs. ‘b’)
where the differences were very small. Thus, there was a statistically
significant association between the Aggressiveness index, as an
expression of tumor aggressiveness, and the Liver index, as an
indicator of liver function.’
Liver Index Score
 
 
Score=4 4<Score≤8 8<Score≤12
pF Comparisons p° p¥
 (a) (b) (c)
 N 197 1636 117     
Aggressiveness Index (M
±SD)  4.92 ± 1.15 5.19 ± 1.51 6.26 ± 1.91 0.0001 (a) vs (b) 0.11 <0.001
      (a) vs (c) <0.0001  
      (b) vs (c) <0.0001  
F Kruskal-Wallis rank test; ° Wilcoxon rank-sum (Mann-Whitney) test; ¥ Test for trend. Abbreviations as in Table 3.
Aggressiveness Index (sum of scores):
MTD(cm) (in tertiles): MTD<4.5; 4.5 ≤ MTD ≤ 9.6; MTD>9.6; for scores 1, 2, 3 respectively;
AFP (ng/ml) (cut-off): AFP<100; 100 ≤ AFP ≤ 1000; AFP>1000; for scores 1, 2, 3 respectively;
PVT (No/Yes): PVT(No); PVT(Yes); for scores 1, 3 respectively;
Nodules (number): Nodules≤3; Nodules>3; for scores 1, 3 respectively.
The Liver Index (sum of scores):
GGTP (IU/ml) (cut-off): GGTP<100; 100 ≤ GGTP ≤ 200; GGTP>200; for scores 1, 2, 3 respectively.
Bilirubin (mg/dl) (cut-off): Bil<1.5; 1.5 ≤ Bil ≤ 2.5; Bil>2.5; for scores 1, 2, 3 respectively.
Albumin (g/dl) (cut-off): Alb>3.5; 2.5 ≤ Alb ≤ 3.5; Alb<2.5; for scores 1, 2, 3 respectively.
Platelets (×109/L) (cut-off): Plt<100; 100 ≤ Plt ≤ 150; Plt>150; for scores 1, 2, 3 respectively
The Liver Index score was divided into three groups: group a, score=4; group b, 4<score ≤ 8; and group c, score>8.
Table 4: Relationship between Liver Index groups a, b and c and Aggressiveness Index Score, in the total cohort.
Furthermore, we examined the trends in the relationships between
the Liver Scores and the individual components of the Aggressiveness
Index (Figure 2) and found that for each of MTD, PVT, multifocality
and AFP, there was a significant trend between the Liver Index score
and the tumor parameter measures.
Figure 2: A) Trends between Liver Index score in categories and:
Maximum Tumor Dimension (cm); B) Alpha-fetoprotein (ng/mL);
C) Portal Vein Thrombosis (yes) (%); D) Number Nodules (>3) (%).
#Test z for trend; ^Mann-Whitney test; ψChi-square test for trend;
§Multiple comparisons of proportions.
Discussion
It has been long accepted that the prognosis of HCC patients
depends on both tumor extent or biology, as well as on liver disease
severity [3] and these twin sets of influences have been incorporated
into most modern staging systems [4-6]. The liver disease component
has recently been modified by inclusion of the semi-quantitative ALBI
(albumin and bilirubin) score [7], as well as the independent role in
prognosis that systemic inflammation has been shown to have for
many tumor types, including HCC, as measured by the serum levels of
C-reactive protein and albumin in the Glasgow score [8]. Serum
albumin levels thus seem to reflect both systemic inflammation (and
nutritional deficiency), as well as synthetic liver function and may even
have a role in protection against HCC growth [9].
The 4 parameters that were incorporated into our Liver Index,
namely, albumin, total bilirubin, platelets and GGTP, were those that
had the highest Hazard Ratios when we examined an HCC
Aggressiveness Index in relation to liver function parameters [2]. This
large HCC cohort has been extensively characterized [1,2,10]. The
Liver Index is comprised of the sum of the scores for these 4
parameters (Table 1) and relates to patient survival, as shown in the
Kaplan-Meier and Cox analysis (Figure 1 and Table 2). Elevated levels
of serum bilirubin are a predominant marker of liver damage or
failure. In the context of HCC, elevated bilirubin levels may result
either from HCC invasion and replacement of liver parenchyma, or of
liver parenchymal damage from the underlying hepatitis or cirrhosis
[10]. Platelet levels, in addition to their role in hemostasis, have been
shown to be a marker of or surrogate for cirrhosis [11,12]. It is in this
context that they can be viewed in our index. However, they have been
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recently been considered, as part of the HCC microenvironment, to be
involved in HCC growth and in HCC drug resistance [13-17].
Furthermore, platelet levels have recently been considered to be a
reflection of 2 HCC phenotypes, based on cirrhosis (small HCCs) or its
absence (larger HCCs) [18,19]. GGTP levels, in addition to their use in
monitoring hepatic damage in disease, also reflect HCC prognosis;
there may also be HCC-specific isoforms and they may be a useful
marker in low alpha-fetoprotein HCC phenotypes [20-23].
The Aggressiveness Index was then evaluated with respect to the
Liver Index and its 4 components, in a Linear Regression Model and a
Multiple Linear Regression model, respectively (Table 3). The
Aggressiveness Index was positively associated with the Liver Index, as
well as with its components, except for albumin, that was negatively
associated, suggesting a protective effect for albumin. We further
considered the relationship between the Aggressiveness and Liver
Indices (Table 4) and found a positive and significant linear trend
between them. We were concerned that at high bilirubin levels, the
Liver Index might simply reflect liver destruction by growing tumor
mass. We therefore re-calculated the Liver Index using a maximum
bilirubin of 3.0 mg/dl. The results were almost identical in the
relationship of the Liver Index to the Aggressiveness Index. We then
examined the trends in the 3 Liver Index scores in relationship to the
Aggressiveness Index components and found a positive and significant
trend, when comparing the lowest to the highest Liver Index scores.
It is of interest to consider the possible mechanisms underlying the
relationships between liver function tests and indices of HCC biology.
Possibly, the changes in liver parameters and the Liver Index with
increased tumor aggressiveness simply reflect liver damage as a
consequence of parenchymal liver invasion and destruction by HCC.
However, given the recent demonstrations of an influence of the
underlying liver on HCC biology and prognosis [24,25], there may be
effects of the liver on the HCC cells, either non-specifically (and the
Liver Index parameters are merely reflections of that) or by direct
interactions between bilirubin, albumin, GGTP and platelets (or
cirrhosis, for which they are a surrogate marker) and HCC cells.
Albumin has already been shown to be protective against HCC growth
[9], while platelets can produce HCC mitogens and inflammatory
cytokines [13,17,26]. GGTP has been recognized as a marker of
experimental hepatocarcinogenesis [27] and may also be involved in
HCC growth and drug resistance [28,29]. Doubtless other liver
function parameters may also be involved in HCC growth or
aggressiveness biology, including microenvironmental inflammatory
cytokines and immune cells. Bilirubin has been thought of as an index
of residual liver function in HCC patients [30] and to relate to alpha-
fetoprotein levels [31].
In conclusion, liver function parameters and the Liver Index
correlated with HCC Aggressiveness and may be directly involved in
the biology (growth and invasiveness) of HCC cells. However, this
Index will need to be externally validated.
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